Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

- PMLiVE

Sanofi opens UK bioscience partnering office

Locates new unit at the Stevenage Bioscience Catalyst

Boehringer to target COPD adherence

Partners with Propeller Health on digital health deal

EU flag

Boehringer’s Giotrif wins new NSCLC licence in Europe

Can now be marketed for advanced squamous cell carcinoma of the lung

- PMLiVE

AbbVie pays $595m upfront for Boehringer psoriasis drug

Says BI 655066 has the potential to become a ‘best-in-class’ treatment

- PMLiVE

Novartis continues to expand its NHS eyecare partnerships

Will work with Plymouth Hospitals NHS Trust to improve patient outcomes

- PMLiVE

Boehringer Ingelheim on walking the talk in patient-centricity

UK medical director Professor Klaus Dugi on patient engagement

- PMLiVE

Boehringer plans €500m biopharma expansion in Austria

New production facility in Vienna will create 400 jobs when it comes online in 2021

Sanofi reception

Sanofi and Boehringer in $20bn asset swap negotiations

Want to exchange their consumer health and veterinary interests

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

Daiichi Sankyo logo

Daiichi Sankyo to shut down German antibody unit U3

Will transfer its operations to a research unit in Japan

Boehringer Ingelheim headquarters

Boehringer pledges €11bn to fund R&D drive

Plans more external collaborations as it appears to reduce spending

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links